Cargando…

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios

INTRODUCTION: Cerebrospinal fluid (CSF) biomarker ratios were never evaluated in late-onset (>65 years) behavioral variant of frontotemporal lobar degeneration (bvFTLD) versus Alzheimer's disease (AD). METHODS: A retrospective monocentric study on 44 clinically suspected amnestic AD or bvFTL...

Descripción completa

Detalles Bibliográficos
Autores principales: Marelli, Cecilia, Gutierrez, Laure-Anne, Menjot de Champfleur, Nicolas, Charroud, Celine, De Verbizier, Delphine, Touchon, Jacques, Douillet, Patrice, Berr, Claudine, Lehmann, Sylvain, Gabelle, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878372/
https://www.ncbi.nlm.nih.gov/pubmed/27239517
http://dx.doi.org/10.1016/j.dadm.2015.06.004
_version_ 1782433557796356096
author Marelli, Cecilia
Gutierrez, Laure-Anne
Menjot de Champfleur, Nicolas
Charroud, Celine
De Verbizier, Delphine
Touchon, Jacques
Douillet, Patrice
Berr, Claudine
Lehmann, Sylvain
Gabelle, Audrey
author_facet Marelli, Cecilia
Gutierrez, Laure-Anne
Menjot de Champfleur, Nicolas
Charroud, Celine
De Verbizier, Delphine
Touchon, Jacques
Douillet, Patrice
Berr, Claudine
Lehmann, Sylvain
Gabelle, Audrey
author_sort Marelli, Cecilia
collection PubMed
description INTRODUCTION: Cerebrospinal fluid (CSF) biomarker ratios were never evaluated in late-onset (>65 years) behavioral variant of frontotemporal lobar degeneration (bvFTLD) versus Alzheimer's disease (AD). METHODS: A retrospective monocentric study on 44 clinically suspected amnestic AD or bvFTLD patients with onset after 65 years and available CSF and clinical data. RESULTS: The final clinical diagnosis was AD (n = 28; 64%), late-onset bvFTLD (n = 14; 32%), and others (n = 2; 4%). Applying the CSF cutoff total-tau/Aβ(1–42) of 1.06, all the bvFTLD were in the FTLD range (<1.06, bvFTLD/FTLD), whereas the AD patients were either in the AD (>1.06, AD/AD) or in the FTLD range (<1.06, AD/FTLD); CSF biomarkers were significantly different in these three groups, but not neuroradiological features or presence of episodic memory deficit. DISCUSSION: Late-onset bvFTLD is underdiagnosed. The available CSF biomarker ratio cutoff need further improvement and overestimated late-onset bvFTLD but could potentially differentiate it from AD, notably in case of conflicting results.
format Online
Article
Text
id pubmed-4878372
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48783722016-05-27 Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios Marelli, Cecilia Gutierrez, Laure-Anne Menjot de Champfleur, Nicolas Charroud, Celine De Verbizier, Delphine Touchon, Jacques Douillet, Patrice Berr, Claudine Lehmann, Sylvain Gabelle, Audrey Alzheimers Dement (Amst) CSF Biomarkers INTRODUCTION: Cerebrospinal fluid (CSF) biomarker ratios were never evaluated in late-onset (>65 years) behavioral variant of frontotemporal lobar degeneration (bvFTLD) versus Alzheimer's disease (AD). METHODS: A retrospective monocentric study on 44 clinically suspected amnestic AD or bvFTLD patients with onset after 65 years and available CSF and clinical data. RESULTS: The final clinical diagnosis was AD (n = 28; 64%), late-onset bvFTLD (n = 14; 32%), and others (n = 2; 4%). Applying the CSF cutoff total-tau/Aβ(1–42) of 1.06, all the bvFTLD were in the FTLD range (<1.06, bvFTLD/FTLD), whereas the AD patients were either in the AD (>1.06, AD/AD) or in the FTLD range (<1.06, AD/FTLD); CSF biomarkers were significantly different in these three groups, but not neuroradiological features or presence of episodic memory deficit. DISCUSSION: Late-onset bvFTLD is underdiagnosed. The available CSF biomarker ratio cutoff need further improvement and overestimated late-onset bvFTLD but could potentially differentiate it from AD, notably in case of conflicting results. Elsevier 2015-06-28 /pmc/articles/PMC4878372/ /pubmed/27239517 http://dx.doi.org/10.1016/j.dadm.2015.06.004 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle CSF Biomarkers
Marelli, Cecilia
Gutierrez, Laure-Anne
Menjot de Champfleur, Nicolas
Charroud, Celine
De Verbizier, Delphine
Touchon, Jacques
Douillet, Patrice
Berr, Claudine
Lehmann, Sylvain
Gabelle, Audrey
Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
title Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
title_full Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
title_fullStr Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
title_full_unstemmed Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
title_short Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
title_sort late-onset behavioral variant of frontotemporal lobar degeneration versus alzheimer's disease: interest of cerebrospinal fluid biomarker ratios
topic CSF Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878372/
https://www.ncbi.nlm.nih.gov/pubmed/27239517
http://dx.doi.org/10.1016/j.dadm.2015.06.004
work_keys_str_mv AT marellicecilia lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT gutierrezlaureanne lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT menjotdechampfleurnicolas lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT charroudceline lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT deverbizierdelphine lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT touchonjacques lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT douilletpatrice lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT berrclaudine lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT lehmannsylvain lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios
AT gabelleaudrey lateonsetbehavioralvariantoffrontotemporallobardegenerationversusalzheimersdiseaseinterestofcerebrospinalfluidbiomarkerratios